Clinical trial
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment…
NCT00365183 · Pharmacyclics LLC., Industry · Terminated
Key facts
| NCT number | NCT00365183 |
|---|---|
| Title | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer |
| Official title | Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Motexafin gadolinium and pemetrexed |
| Enrollment | 74 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Aug 17, 2006 |
| Last update posted | Oct 31, 2013 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: